FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166552783> ?p ?o ?g. }

• W3166552783 endingPage "49" @default.
• W3166552783 startingPage "48" @default.
• W3166552783 abstract "Background: HTI is a novel HIV vaccine immunogen designed at redirecting cellular immune responses to HIV targets associated with viral control. Methods: The AELIX-002 trial (NCT03204617) was a randomized, singlecenter, placebo-controlled trial to evaluate the safety, immunogenicity and antiviral effect of DNA.HTI (D), MVA.HTI (M) and ChAdOx1.HTI (C) vaccines after discontinuation of ART in early-treated people living with HIV (PLWH). 45 participants were randomized (2:1) to receive heterologous prime-boost vaccination regimens consisting of DDDMM followed by CCM, or matched placebo (P). During a 24-week analytical treatment interruption (ATI), plasma viral load (pVL) was monitored weekly and ART was resumed if pVL >100,000 copies/mL, or >10,000 copies/mL over 8 weeks, and/or CD4 2-fold increase in HTI-specific T cell responses compared to baseline). Median (range) increase in total frequencies of HTI-specific T cells from baseline was 1,499 (120 to 3,150) SFC/million PBMC. At time of ATI start, 71% (0 to 100) of the total anti- HIV-1 T-cell response was HTI-specific. For participants without any potentially beneficial HLA class I alleles (32 of the 41), 8 (40%) of the vaccinees and 1 (8%) of the placebo recipients were able to remain off ART for 22 weeks (Δ 32%, 80%CI [7.6;55.7]);with pVL <2,000 copies/mL being observed in 5 and 1 vaccine and placebo recipients, respectively. Magnitude of HTI-specific responses at the time of ATI start positively correlated with time off ART in vaccinees (Rho 0.65, p < 0.01). Decay in total or intact HIV proviral DNA from baseline to ATI was similar between vaccine and placebo arms. Conclusion: HTI vaccines were safe and highly immunogenic in early-treated PLWH with a prolonged time off ART seen in vaccinees with non-beneficial HLA class I alleles. Time off ART positively correlated with vaccine-induced HTIspecific T cell responses at ATI start. Multivariate analysis for other correlates of response is ongoing. These encouraging data strongly support the use of HTIbased vaccines as the backbone of combination cure regimens such as with the TLR7 agonist vesatolimod, which is currently being evaluated in the AELIX-003 study (NCT04364035)." @default.
• W3166552783 created "2021-06-22" @default.
• W3166552783 creator A5002960167 @default.
• W3166552783 creator A5009903397 @default.
• W3166552783 creator A5010352788 @default.
• W3166552783 creator A5014702693 @default.
• W3166552783 creator A5028130303 @default.
• W3166552783 creator A5033328243 @default.
• W3166552783 creator A5033466901 @default.
• W3166552783 creator A5058306976 @default.
• W3166552783 creator A5068859868 @default.
• W3166552783 creator A5077474883 @default.
• W3166552783 creator A5082553853 @default.
• W3166552783 creator A5085739911 @default.
• W3166552783 creator A5090367243 @default.
• W3166552783 date "2021-01-01" @default.
• W3166552783 modified "2023-09-26" @default.
• W3166552783 title "A placebo-controlled ati trial of HTI vaccines in early treated HIV infection" @default.
• W3166552783 hasPublicationYear "2021" @default.
• W3166552783 type Work @default.
• W3166552783 sameAs 3166552783 @default.
• W3166552783 citedByCount "0" @default.
• W3166552783 crossrefType "journal-article" @default.
• W3166552783 hasAuthorship W3166552783A5002960167 @default.
• W3166552783 hasAuthorship W3166552783A5009903397 @default.
• W3166552783 hasAuthorship W3166552783A5010352788 @default.
• W3166552783 hasAuthorship W3166552783A5014702693 @default.
• W3166552783 hasAuthorship W3166552783A5028130303 @default.
• W3166552783 hasAuthorship W3166552783A5033328243 @default.
• W3166552783 hasAuthorship W3166552783A5033466901 @default.
• W3166552783 hasAuthorship W3166552783A5058306976 @default.
• W3166552783 hasAuthorship W3166552783A5068859868 @default.
• W3166552783 hasAuthorship W3166552783A5077474883 @default.
• W3166552783 hasAuthorship W3166552783A5082553853 @default.
• W3166552783 hasAuthorship W3166552783A5085739911 @default.
• W3166552783 hasAuthorship W3166552783A5090367243 @default.
• W3166552783 hasConcept C126322002 @default.
• W3166552783 hasConcept C137061746 @default.
• W3166552783 hasConcept C142462285 @default.
• W3166552783 hasConcept C142724271 @default.
• W3166552783 hasConcept C159654299 @default.
• W3166552783 hasConcept C168563851 @default.
• W3166552783 hasConcept C185592680 @default.
• W3166552783 hasConcept C202751555 @default.
• W3166552783 hasConcept C203014093 @default.
• W3166552783 hasConcept C204787440 @default.
• W3166552783 hasConcept C22070199 @default.
• W3166552783 hasConcept C27081682 @default.
• W3166552783 hasConcept C2777704310 @default.
• W3166552783 hasConcept C2778190748 @default.
• W3166552783 hasConcept C2778715236 @default.
• W3166552783 hasConcept C2779909307 @default.
• W3166552783 hasConcept C2780195530 @default.
• W3166552783 hasConcept C2780868878 @default.
• W3166552783 hasConcept C3013748606 @default.
• W3166552783 hasConcept C542903549 @default.
• W3166552783 hasConcept C55493867 @default.
• W3166552783 hasConcept C71924100 @default.
• W3166552783 hasConcept C8891405 @default.
• W3166552783 hasConceptScore W3166552783C126322002 @default.
• W3166552783 hasConceptScore W3166552783C137061746 @default.
• W3166552783 hasConceptScore W3166552783C142462285 @default.
• W3166552783 hasConceptScore W3166552783C142724271 @default.
• W3166552783 hasConceptScore W3166552783C159654299 @default.
• W3166552783 hasConceptScore W3166552783C168563851 @default.
• W3166552783 hasConceptScore W3166552783C185592680 @default.
• W3166552783 hasConceptScore W3166552783C202751555 @default.
• W3166552783 hasConceptScore W3166552783C203014093 @default.
• W3166552783 hasConceptScore W3166552783C204787440 @default.
• W3166552783 hasConceptScore W3166552783C22070199 @default.
• W3166552783 hasConceptScore W3166552783C27081682 @default.
• W3166552783 hasConceptScore W3166552783C2777704310 @default.
• W3166552783 hasConceptScore W3166552783C2778190748 @default.
• W3166552783 hasConceptScore W3166552783C2778715236 @default.
• W3166552783 hasConceptScore W3166552783C2779909307 @default.
• W3166552783 hasConceptScore W3166552783C2780195530 @default.
• W3166552783 hasConceptScore W3166552783C2780868878 @default.
• W3166552783 hasConceptScore W3166552783C3013748606 @default.
• W3166552783 hasConceptScore W3166552783C542903549 @default.
• W3166552783 hasConceptScore W3166552783C55493867 @default.
• W3166552783 hasConceptScore W3166552783C71924100 @default.
• W3166552783 hasConceptScore W3166552783C8891405 @default.
• W3166552783 hasIssue "1" @default.
• W3166552783 hasLocation W31665527831 @default.
• W3166552783 hasOpenAccess W3166552783 @default.
• W3166552783 hasPrimaryLocation W31665527831 @default.
• W3166552783 hasRelatedWork W1592348533 @default.
• W3166552783 hasRelatedWork W1970430579 @default.
• W3166552783 hasRelatedWork W2013006914 @default.
• W3166552783 hasRelatedWork W2033462010 @default.
• W3166552783 hasRelatedWork W2074061250 @default.
• W3166552783 hasRelatedWork W2083008217 @default.
• W3166552783 hasRelatedWork W2092700072 @default.
• W3166552783 hasRelatedWork W2102578701 @default.
• W3166552783 hasRelatedWork W2115625797 @default.
• W3166552783 hasRelatedWork W2125052178 @default.
• W3166552783 hasRelatedWork W2153650518 @default.
• W3166552783 hasRelatedWork W2170838597 @default.

• next